Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorSobczak, Amélie I. S.
dc.contributor.authorPitt, Samantha J.
dc.contributor.authorStewart, Alan J.
dc.date.accessioned2018-06-04T11:30:17Z
dc.date.available2018-06-04T11:30:17Z
dc.date.issued2018-06
dc.identifier.citationSobczak , A I S , Pitt , S J & Stewart , A J 2018 , ' Glycosaminoglycan neutralization in coagulation control ' , Arteriosclerosis, Thrombosis, and Vascular Biology , vol. 38 , no. 6 , pp. 1258-1270 . https://doi.org/10.1161/ATVBAHA.118.311102en
dc.identifier.issn1524-4636
dc.identifier.otherPURE: 252741076
dc.identifier.otherPURE UUID: 2b31dafc-ddff-43d9-9e46-8b2c7f11ea78
dc.identifier.otherPubMed: 29674476
dc.identifier.otherScopus: 85051818363
dc.identifier.otherWOS: 000439571100011
dc.identifier.urihttp://hdl.handle.net/10023/13695
dc.descriptionThis work was supported by the British Heart Foundation (grant codes: PG/15/9/31270 and FS/15/42/31556). S.J. Pitt is supported by a Royal Society of Edinburgh Biomedical Fellowship (XRE013).en
dc.description.abstractThe glycosaminoglycans (GAGs) heparan sulfate, dermatan sulfate and heparin are important anticoagulants that inhibit clot formation through interactions with antithrombin and heparin cofactor II. Unfractionated heparin, low molecular weight heparin and heparin-derived drugs are often the main treatments used clinically to handle coagulatory disorders. A wide range of proteins have been reported to bind and neutralise these GAGs to promote clot formation. Such neutralising proteins are involved in a variety of other physiological processes, including inflammation, transport and signalling. It is clear that these interactions are important for the control of normal coagulation and influence the efficacy of heparin and heparin-based therapeutics. In additon to neutralisation, the anticoagulant activities of GAGs may also be regulated through reduced synthesis or by degradation. In this review we describe GAG neutralisation, the proteins involved and the molecular processes that contribute to the regulation of anticoagulant GAG activity.
dc.format.extent14
dc.language.isoeng
dc.relation.ispartofArteriosclerosis, Thrombosis, and Vascular Biologyen
dc.rights© 2018 The Authors. Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.en
dc.subjectDermatan sulfateen
dc.subjectGlycosaminoglycanen
dc.subjectHeparan sulfateen
dc.subjectHeparinen
dc.subjectThrombosisen
dc.subjectQH301 Biologyen
dc.subjectQP Physiologyen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectT-NDASen
dc.subject.lccQH301en
dc.subject.lccQPen
dc.subject.lccRMen
dc.titleGlycosaminoglycan neutralization in coagulation controlen
dc.typeJournal itemen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.School of Medicineen
dc.contributor.institutionUniversity of St Andrews.Cellular Medicine Divisionen
dc.contributor.institutionUniversity of St Andrews.Institute of Behavioural and Neural Sciencesen
dc.contributor.institutionUniversity of St Andrews.Biomedical Sciences Research Complexen
dc.identifier.doihttps://doi.org/10.1161/ATVBAHA.118.311102
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record